Methyl 2-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]acetate | 1374784-93-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methyl 2-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]acetate
• CAS: 1374784-93-6
• 化学式: C₂₁H₂₁NO₆
• 分子量: 383.401
• InChiKey: UDPWHFASGFJTSQ-UHFFFAOYSA-N

物化性质

• 沸点：
  512.3±50.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  76.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Methyl 2-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]acetate 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.5h， 生成 2-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-N-(5-ethyl-1H-pyrazol-3-yl)acetamide
  参考文献：
  名称：

  Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases

  摘要：

  A new series of quinoline ether inhibitors, which potently and selectively inhibit PDGFR tyrosine kinases, is described in this Letter. Compounds 23 and 33 are selective, low nanomolar inhibitors of PDGFR alpha and beta, display good pharmacokinetics in rat and dog and are active in vivo at low doses when given orally twice daily. Further evaluation of these compounds is warranted. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.074
• 作为产物：
  描述：

  2-(4-羟基-2-甲氧基苯基)乙酸甲酯 、 4-氯 -6,7-二甲氧基喹啉 在 4-二甲氨基吡啶 作用下， 以 氯苯 为溶剂， 反应 6.0h， 以58%的产率得到Methyl 2-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]acetate
  参考文献：
  名称：

  Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases

  摘要：

  A new series of quinoline ether inhibitors, which potently and selectively inhibit PDGFR tyrosine kinases, is described in this Letter. Compounds 23 and 33 are selective, low nanomolar inhibitors of PDGFR alpha and beta, display good pharmacokinetics in rat and dog and are active in vivo at low doses when given orally twice daily. Further evaluation of these compounds is warranted. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.074